Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera
Journal
European journal of drug metabolism and pharmacokinetics
ISSN: 2107-0180
Titre abrégé: Eur J Drug Metab Pharmacokinet
Pays: France
ID NLM: 7608491
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
19
04
2023
medline:
7
7
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
Lu-177 DOTATATE (Lutathera From a retrospective study, SPECT/CT images were acquired at 4 h, 24 h, 72 h, and 192 h postadministration. From these images, volumic activities were calculated in blood and bone marrow. An individual non-compartmental pharmacokinetic analysis was performed, and the mean pharmacokinetic parameters of each tissue were compared together and with reference data. Blood volumic activities were then used to perform a population pharmacokinetic analysis (NONMEM). The pharmacokinetic parameters (non-compartmental analysis) obtained from blood (clearance [CL] = 2.65 L/h, volume of distribution at steady state [Vss] = 309 L, elimination half-life [t This study is a proof of concept that obtaining pharmacokinetic parameters with image-based blood concentration is possible. Obtaining observed concentrations from SPECT/CT images, without the need for blood sampling, is a real advantage for the patient and the drug monitoring. Pharmacokinetic modeling could be combined with a deep learning model for automatic contouring and allow precise patient-specific dose adjustment in a non-invasive manner.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Lu-177 DOTATATE (Lutathera
METHODS
METHODS
From a retrospective study, SPECT/CT images were acquired at 4 h, 24 h, 72 h, and 192 h postadministration. From these images, volumic activities were calculated in blood and bone marrow. An individual non-compartmental pharmacokinetic analysis was performed, and the mean pharmacokinetic parameters of each tissue were compared together and with reference data. Blood volumic activities were then used to perform a population pharmacokinetic analysis (NONMEM).
RESULTS
RESULTS
The pharmacokinetic parameters (non-compartmental analysis) obtained from blood (clearance [CL] = 2.65 L/h, volume of distribution at steady state [Vss] = 309 L, elimination half-life [t
CONCLUSION
CONCLUSIONS
This study is a proof of concept that obtaining pharmacokinetic parameters with image-based blood concentration is possible. Obtaining observed concentrations from SPECT/CT images, without the need for blood sampling, is a real advantage for the patient and the drug monitoring. Pharmacokinetic modeling could be combined with a deep learning model for automatic contouring and allow precise patient-specific dose adjustment in a non-invasive manner.
Identifiants
pubmed: 37184824
doi: 10.1007/s13318-023-00829-5
pii: 10.1007/s13318-023-00829-5
doi:
Substances chimiques
lutetium Lu 177 dotatate
AE221IM3BB
copper dotatate CU-64
0
Lutetium-177
BRH40Y9V1Q
Radioisotopes
0
Radiopharmaceuticals
0
Lutetium
5H0DOZ21UJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-339Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. Multidisciplinary Digital Publishing Institute; 2019;12:114.
Pouget J-P, Santoro L, Piron B, Paillas S, Ladjohounlou R, Pichard A, et al. From the target cell theory to a more integrated view of radiobiology in targeted radionuclide therapy: The Montpellier group’s experience. Nucl Med Biol. 2021;104–105.
Gupta SK, Singla S, Thakral P, Bal CS. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE. Clin Nucl Med. 2013;38:188–94.
doi: 10.1097/RLU.0b013e3182814ac1
pubmed: 23412597
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.
doi: 10.1007/s00259-011-1902-1
pubmed: 21892623
Sabet A, Ezziddin K, Pape U-F, Ahmadzadehfar H, Mayer K, Pöppel T, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54:1857–61.
doi: 10.2967/jnumed.112.119347
pubmed: 24009272
Del Prete M, Buteau F-A, Arsenault F, Saighi N, Bouchard L-O, Beaulieu A, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728–42.
doi: 10.1007/s00259-018-4209-7
pubmed: 30506283
Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49:3830–40.
doi: 10.1007/s00259-022-05786-w
pubmed: 35451612
pmcid: 9399027
Siebinga H, de Wit-van der Veen BJ, Stokkel MDM, Huitema ADR, Hendrikx JJMA. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review. Theranostics. Ivyspring International Publisher; 2022;12:7804–20.
Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138–46.
doi: 10.1007/s00259-009-1072-6
pubmed: 19247653
pmcid: 2691529
Santoro L, Pitalot L, Trauchessec D, Mora-Ramirez E, Kotzki PO, Bardiès M, et al. Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res. 2021;11:1.
Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med. 2002;43:1245–53.
pubmed: 12215566
PKanalix version 2021R2. Antony, France: Lixoft SAS, 2021. Available from: https://lixoft.com/products/pkanalix/ . Access date: 04/04/2022.
FDA, Highlights of prescribing information - LUTATHERA - 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf . Access date: 04/02/2022.
Nolain P, Combet R, Marchionni D, Speth H, Martinez JM, Fabre D. PopkinR: a suite of Shiny applications focused on the pharmacometrics workflow. Poster presented to Population Approach Group Europe (PAGE) meeting. Switzerland, 2018. https://www.page-meeting.org/?abstract=8684 . Access date: 07/04/2023.
Lindbom L, Pihlgren P, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.
doi: 10.1016/j.cmpb.2005.04.005
pubmed: 16023764
Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.
doi: 10.1016/j.cmpb.2003.11.003
pubmed: 15212851
Hagmarker L, Svensson J, Rydén T, van Essen M, Sundlöv A, Gleisner KS, et al. Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases. J Nucl Med. 2019;60:1406–13.
doi: 10.2967/jnumed.118.225235
pubmed: 30902877
pmcid: 6785794
Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E. Evaluation of the interaction of amino acid infusion on 177Lu-dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors. Clin Pharmacokinet. 2019;58:213–22.
doi: 10.1007/s40262-018-0674-1
pubmed: 29736841
Jiménez-Franco LD, Glatting G, Prasad V, Weber WA, Beer AJ, Kletting P. Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: an in silico analysis for standard and optimized treatment. J Nucl Med. 2021;62:92–8.
doi: 10.2967/jnumed.120.245068
pubmed: 32646878
Chan Kwong AH-XP, O'Jeanson A and Khier S. Model-informed therapeutic drug monitoring of meropenem in critically ill patients: improvement of the predictive ability of literature models with the PRIOR approach. Eur J Drug Metab Pharmacokinet. 2021 ;46(3):415-426.
Chan Kwong AH-XP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47:431–46.
Lutathera European public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/lutathera-epar-public-assessment-report_en.pdf . Accessed on 02 July 2022.
Lubberink M, Wilking H, Öst A, Ilan E, Sandström M, Andersson C, et al. In vivo instability of 177 Lu-DOTATATE during peptide receptor radionuclide therapy. J Nucl Med. 2020;61(9):1337–40.
doi: 10.2967/jnumed.119.237818
pubmed: 32005767
pmcid: 7456166
Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151-62.